CNCNYSEHospital & Medical Service PlansFiscal year ends December 31

CENTENE CORP

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026

$68.63−0.53 (-0.77%)

Close on Oct 19, 2026

Market cap: $34.15B
P/E (TTM): –
Dividend yield: –

CENTENE CORP income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31
Revenue	194,777	163,071	153,999	144,547	125,982	111,115	74,639	60,116	48,382	40,607	22,760	16,560	10,863	8,110	5,211	4,448	4,103	3,365
Cost of Revenue	2,670	2,729	3,564	7,032	4,894	3,303	2,465	2,386	1,847	1,864	1,621	1,280	327	88	78	64	61	57
Gross Profit	14,209	17,069	17,637	16,918	14,487	107,812	72,174	57,730	46,535	38,743	21,139	15,280	10,536	8,022	5,133	4,384	4,042	3,308
Selling, General & Admin	12,904	12,400	12,563	11,589	9,601	9,380	6,533	6,043	4,446	3,673	1,802	1,298	–	–	–	–	–	–
General & Administrative	–	–	–	–	–	–	–	–	–	–	1,826	1,314	931	677	578	478	448	445
Total Costs & Expenses	202,400	159,896	151,069	143,229	124,198	108,033	72,858	58,658	47,183	39,344	22,055	16,096	10,586	8,002	5,008	4,291	3,965	3,233
Operating Income	-7,623	3,175	2,930	1,318	1,784	3,082	1,781	1,458	1,199	1,263	705	464	277	108	204	157	138	132
Interest Expense	678	702	725	665	665	728	412	343	255	217	43	35	27	20	20	18	16	17
Income from Equity Investments	–	–	–	–	–	–	–	–	3.00	5.00	8.00	6.00	–	–	–	–	–	–
Other Non-Operating Income	895	1,082	668	644	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	7,311	13	529	2,318	229	72	271	0	0	0	38	0	0	-26	–	–	–	–
Gain (Loss) on Investments	–	–	–	–	–	–	–	–	–	–	–	–	–	1.48	0.29	6.34	0.14	4.99
Gain (Loss) on Sale of Assets	2.00	120	152	-221	-12	-5.00	0	0	–	–	–	–	–	–	–	–	–	–
Legal Settlements	–	–	0	0	-1,250	0	0	–	–	–	–	–	–	–	–	–	–	–
Pretax Income	-6,728	4,257	3,598	1,962	1,813	2,773	1,782	1,368	1,134	1,160	697	457	269	123	188	154	138	137
Income Tax Expense	-51	963	899	760	477	979	473	474	326	599	339	196	107	47	71	60	49	52
Income from Continuing Operations	–	–	–	–	–	–	–	–	828	559	356	268	161	89	121	91	86	84
Income from Discontinued Operations	–	–	–	–	–	–	–	–	0	3.00	-1.00	3.00	4.00	-87	-9.30	3.89	-2.42	-0.68
Net Income incl. Noncontrolling Interests	-6,677	3,294	2,699	1,202	1,336	1,794	1,309	894	808	561	357	264	166	-11	108	98	86	83
Minority Interest in Earnings	-3.00	-11	-3.00	0	-11	-14	-12	-6.00	-20	-1.00	2.00	-7.00	1.00	-13	-2.86	3.44	2.57	0
Net Income	-6,674	3,305	2,702	1,202	1,347	1,808	1,321	900	828	562	355	271	165	2.00	111	95	84	83
EPS (Basic)(per share)	-13.53	6.33	4.97	2.09	2.31	3.17	3.19	2.31	2.40	1.76	1.49	1.17	0.76	0.01	0.56	0.49	0.49	0.48
EPS (Diluted)(per share)	-13.53	6.31	4.95	2.07	2.28	3.12	3.14	2.26	2.34	1.71	1.44	1.13	0.74	0.01	0.53	0.47	0.47	0.47
Shares Outstanding (Basic, Weighted)(shares)	493	522	543	575	583	571	413	390	345	319	238	233	217	206	201	195	172	173
Shares Outstanding (Diluted, Weighted)(shares)	493	524	546	582	591	579	420	399	353	328	246	241	225	215	210	202	177	178
EBITDA	-6,348	4,416	4,223	2,748	3,119	4,341	2,424	1,953	1,560	1,541	816	553	344	174	262	209	182	167
Premiums Earned	–	–	–	–	–	–	–	–	43,353	35,399	19,389	14,198	10,153	7,569	4,948	4,192	3,787	–
Policyholder Benefits & Claims	157,702	125,707	118,894	111,529	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 8.0%
Operating margin: -2.8%
Net margin: -2.5%
Return on equity, FY2025: -28.8%

Financial strength

Current ratio: 1.15
Debt to equity: 0.71
Debt to assets: 19.4%
Cash to current liabilities: 59.3%

Valuation

P/E ratio: –
Price to sales: 0.17
Price to book: 1.51
Dividend yield: –